AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
2.180
-0.170 (-7.23%)
At close: Jul 30, 2025, 4:00 PM
2.170
-0.010 (-0.46%)
After-hours: Jul 30, 2025, 5:09 PM EDT
AC Immune Employees
As of December 31, 2024, AC Immune had 172 total employees, including 133 full-time and 39 part-time employees. The number of employees increased by 11 or 6.83% compared to the previous year.
Employees
172
Change (1Y)
11
Growth (1Y)
6.83%
Revenue / Employee
$186,129
Profits / Employee
-$342,563
Market Cap
215.70M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 172 | 11 | 6.83% |
Dec 31, 2023 | 161 | 5 | 3.21% |
Dec 31, 2022 | 156 | 7 | 4.70% |
Dec 31, 2020 | 149 | 17 | 12.88% |
Dec 31, 2019 | 132 | 28 | 26.92% |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ACIU News
- 3 months ago - AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 4 months ago - AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease - GlobeNewsWire
- 4 months ago - AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 - GlobeNewsWire
- 4 months ago - AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 9 months ago - AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients - Benzinga
- 1 year ago - AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 - GlobeNewsWire
- 1 year ago - AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward - Seeking Alpha
- 1 year ago - AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease - GlobeNewsWire